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I. Introduction
Intensity-modulated radiation therapy (IMRT) is the most common method of external beam radiation treatment for prostate cancer patients.
1 Treatment planning optimization can be used in prostate cancer IMRT treatment planning to find a treatment plan that determines the best trade-off between a set of conflicting objectives. One way to formulate 55 such a problem is to assign each objective a weight representing its relative importance and then combine all objectives into a single objective function.
In treatment planning, objective function weights are typically seen as tuneable parameters. Planners usually solve the treatment planning problem iteratively, tuning the weights in a trial and error approach, until a resulting plan is deemed acceptable. [2] [3] [4] [5] This a priori 60 approach is widely used in clinical practice, though it can be inefficient and time-consuming.
More recently, research has focused on exploring the Pareto surface of the treatment planning problem. [6] [7] [8] [9] [10] [11] This a posteriori approach allows a treatment planner to choose a final plan from a large database of already optimized plans. Once a plan is chosen, it is possible to automate the planning process by using the reference plan's DVH trade-offs to guide the algorithm. 11 In all cases, treatment planning effort can be reduced by starting from a "good" set of weights.
Recent advances in inverse optimization have demonstrated the potential of deriving objective function weights from historical treatment plans. 12 The inverse optimization method takes a historical treatment plan (i.e., already optimized and delivered) and determines the 70 values of the objective function weights that are needed to recreate the given plan. Using such a method to retrospectively determine weights lets us better understand the relationship between weights and the optimized dose distribution. A recent study provided a proof-ofconcept for geometry-driven weight determination in prostate cancer. 13 In particular, they developed a statistical model to relate inversely optimized objective function weights and 75 patient anatomy, and quantify the trade-off between rectum and bladder sparing. Such a model can be used in a predictive manner to determine a set of initial weights for treatment planning for future patients, personalized to their anatomy.
Related studies have considered using geometric features to predict dose objectives or dose volume histograms (DVHs) for IMRT treatment planning and quality control. 14-25 Such 80 methods generally fall into two categories. The first approach, which we will refer to as the "library method," uses a database of previously delivered clinical plans from which the final plan or dose objective for the new patient is chosen as is. 14- 19 The second approach, which we will refer to as the "prediction method," uses an internal geometric quantifier like an overlap volume histogram (OVH) to predict the dose for a single organ-at-risk (OAR), such 85 as the rectum. [20] [21] [22] [23] [24] [25] Although the predicted dose can be used to guide the planning process, the planner is still required to manually tune the weights in order to achieve the desired plan. to generate those plans. The IOM was derived from a forward optimization problem (FOP), which corresponds to the treatment planning optimization problem. The FOP objective was a weighted function composed of five objectives corresponding to the bladder, rectum, left femoral head, right femoral head, and PTV ring, which we will index by B, R, LF, RF, and P R, respectively. PTV ring is an artificial structure comprising a ring around the
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PTV and is used to achieve better dose conformity at Princess Margaret. Although the treatment planning problem solved in clinical practice has many more objectives, it was shown that our formulation is able to closely replicate clinical quality plans with optimal weights. 12 Therefore, the treatment plans generated by the IOM weights (i.e., IOM plans)
will be treated as a proxy for the clinical plans.
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We now briefly review the FOP and refer the interested reader to the literature for a detailed description. 13 The FOP penalizes the dose to an OAR k linearly, when it is above some threshold θ k . We set our threshold to 50 Gy for the bladder, rectum, and PTV ring.
We penalize the maximum dose to the left and right femoral heads. The upper bound on the dose delivered to all voxels was set to 81.9 Gy while the lower bounds on the dose delivered
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to the CTV and PTV were set to 78 Gy and 74.1 Gy, respectively. We used lower bounds for the dose delivered to the CTV and PTV because they are generally assigned very large weights.
We applied the IOM to all 315 patients resulting in a vector of five weights for each patient, which we refer to as the "IOM weights." All patients had IOM plans with clinical
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DVH metrics that were within 10% of the historical plans' metrics. The inversely determined objective function weights were then used as the ground truth in order to train and test our prediction models. The majority of the weight is split between the bladder and rectum while both femurs and PTV ring receive very little. The IOM weights for five sample patients, chosen to illustrate a full range of weight values, are shown in Table I along with   145 the population average of the IOM weights across all 315 patients. The five sample patients are constant in the tables throughout this paper and will be referred to as "cohort S." 
C. Quantifying Patient Geometry
We used overlap volume histograms (OVHs) to quantify patient anatomy. 14 We generated OVH curves for the bladder and rectum using PTV expansions of 0 cm to 2.5 cm in 0.1 150 cm increments. In order to capture the spatial tradeoff between the bladder and rectum, we then computed the ratio of rectum overlap volume to bladder overlap volume for each PTV expansion value x ∈ {0, 0.1, ..., 2.5}, which we denote as OV x . This yielded a total of 26 OV x values for each patient. Next, we computed the slope of the bladder and rectum OVH curves at points interpolated between each pair of consecutive expansion points in 155 {0, 0.1, ..., 2.5}. This resulted in an additional 50 features for each patient, which we denote by OV SB x,x+0.1 and OV SR x,x+0.1 for the bladder and rectum, respectively. Thus, in total, we derived 76 features from the OVHs for each patient. These features were then used as potential independent variables in our prediction models.
D. Weight Prediction
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We trained three weight prediction models using the IOM weights from Section B and the patient features described in Section C. We began with a logistic regression model, which captures the primary trade-off between the bladder and rectum. To generalize our approach for more complicated tumor sites with many OARs nearby, we developed a weighted K-nearest neighbor model and a multinomial logistic regression model, which can simulta-
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neously predict any number of weight values.
Due to the dimensionality of our feature space, it was not feasible to consider all possible combinations of features. Instead, for each model we first considered all possible one-and two-feature models from which the best was chosen using a specified criteria outlined in the individual model sections below. We then employed stepwise forward regression to determine 170 if any further variables improved the model.
If such an approach were to be implemented clinically, we would expect the models to be trained on all past patient data and used to predict a single new patient. To simulate this idea, we employed a leave-one-out approach for each model. In other words, we set aside a single patient and trained our models using the remaining 314 patients. The resulting model 175 is then used to predict the remaining out-of-sample patient. This process was repeated 315 times, once for each possible out-of-sample patient. All statistical work was carried out using the software language R.
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Logistic Regression
Due to the bi-criteria nature of prostate cancer treatment planning, it was intuitive to 180 first apply a logistic regression model that predicts the bladder weight from a set of patient features. The rectum weight was then computed by subtracting the bladder weight from 1. We also considered predicting the rectum weight but found the bladder weight model to be slightly more accurate. Because of the low weight values of the left femoral head, right femoral head, and PTV ring (see Table I ), they were fixed to 0 during the regression
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and then set to the population averages of 0.003, 0.003, and 0.05, respectively, post hoc.
Finally, the bladder and rectum weights were scaled down by a factor of 0.944 to ensure that the weights sum to one. This logistic regression approach improves upon a previous approach in the literature 13 by predicting bladder and rectum weights on the full interval Our logistic regression selection criteria consisted of two steps: 1) Identify the models with statistically significant independent variables (i.e., features) at the 95% level using the Wald Test, 28 and 2) Choose the model with the smallest Akaike information criterion (AIC)
value. 28 Using the approach described above, the best model used two patient features, OV 0.4
and OV SR 0,0.1 . The functional form of the logistic regression equation is
where α B denotes the bladder weight.
Multinomial Logistic Regression
Next, we trained a multinomial logistic regression model that simultaneously predicts all 
where α B , α R , α LF , α RF , and α P R denote the bladder weight, rectum weight, left femoral 200 head weight, right femoral head weight, and PTV ring weight, respectively.
K-Nearest Neighbor
The third approach we considered was a classification-based model that combines k-means clustering and weighted K-nearest neighbors. We used a k-means clustering algorithm 29 to partition the IOM weights into 3 (i.e., k = 3) distinct groups, corresponding to patients that 205 are bladder-weighted, rectum-weighted, and roughly equally weighted or balanced. Each patient was assigned a label corresponding to the cluster to which that patient belonged.
Using the patient labels, we trained a distance-weighted K-nearest neighbor (KNN) model, which uses a set of patient features to determine the probability that a given patient belongs to each cluster. 30 Once our features were selected, we determined the K-nearest neighbors in feature space using Euclidean distance. We then used a kernel function to value each neighbor according to distance, with closer neighbors receiving a higher value.
The probability of a patient belonging to cluster i equaled the summation of values for all neighbors belonging to cluster i (determined via labelling) divided by the summation of values for all K neighbors. The three probabilities and the corresponding centroid weight vectors were then used to assign an expected weight vector to each patient. Let b, r, and n index the bladder, rectum, and balanced clusters, respectively. Let p i denote the probability of belonging to cluster i and c i denote the centroid weight vector of cluster i. For each patient, the KNN predicted weight vector, α KN N , was
Our model selection process consisted of determining the most predictive patient features, choosing the best kernel function, and finding the optimal value of K. For each feature combination, we considered five kernel functions (rectangular, triangular, Epanechnikov,
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Gaussian, and rank) and all values of K ≤ 50. From these 250 models, we chose the model with the highest classification accuracy. This process was repeated for each set of features.
Classification accuracy was determined by assigning each patient to the cluster for which that patient has the highest probability of belonging (i.e., the largest p i ). These labels were then compared against the original labelling from k-means clustering and the proportion with K = 14.
E. Metrics
To compare the weights from the different models, we computed the absolute difference 220 between each model's predicted weights and the IOM weights for each patient. The Pop.
Avg. weight vector was used as a baseline performance measure.
To assess the clinical applicability of our models, five treatment plans and dose distributions were generated for each patient using the weight vectors from the IOM (representing the ground truth), LR model, MLR model, KNN model, and the population average IOM 225 weight vector ("Pop. Avg."). From the dose distributions, we measured the following metrics, which are derived from the clinical DVH acceptability criteria used at Princess Margaret Cancer Centre: V54.3Gy and V70Gy for both the bladder and the rectum, and V54.3Gy for the femoral heads. We also computed the voxel-by-voxel absolute dose difference between the IOM dose distribution and the predicted dose distribution in the bladder, rectum, CTV,
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and PTV. From these difference distributions, we calculated each patient's median and 95th
percentile dose difference. All comparisons between different models (either weights directly or dosimetric differences) were tested for statistical significance using the Mann-WhitneyWilcoxon Test.
28 Figure 1 provides a graphical overview of our methodology from input data, to model training, to prediction, to metrics analysis. 
III. Results
A. Weight Prediction
To illustrate the results of each model, we provide examples of the predicted weight vectors for cohort S. Tables II, III, The bladder weight plotted against OV 0.4 , the main predictor in all our models, is shown in Figure 2 . An OV 0.4 < 1 implies that more bladder volume overlaps with the tumor than rectum volume, and hence, the bladder objective should receive more weight. The regression parameters for the logistic model were β 0 = 6.44, β 1 = −7.41, and β 2 = 7.26. For (across all leave-one-out iterations) for the rectum, which were β R,0 = −6.69 and β R,1 = 6.60 and the PTV ring, which were β P R,0 = −6.30 and β P R,1 = 4.27. In all cases tested, the regression parameters corresponding to the left and right femoral heads were insignificant. 
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B. Weight Comparison
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For each patient, we computed the absolute difference between each model's predicted weights and the IOM weights to measure prediction error between the models. Figure 4 shows the median absolute difference, across all patients, between the IOM weights and the weights derived from the KNN model, LR model, MLR model, and Pop. Avg. The LR model performs the best for the bladder and rectum, with a median weight error that is 
C. Plan Comparison
As mentioned in Section II.E., we generated five treatment plans for each patient to compare how well the model predicted plans replicated the IOM plans. We first consider 270 the clinical metrics for each patient's plan, which include bladder V54.3Gy and V70Gy, and rectum V54.3Gy and V70Gy. We compute the absolute difference between the metrics derived from the model predicted plans and the metrics derived from the IOM plans. Figure   5 do not differ from each other. Similarly, the LR model continues to trend towards the best across all metrics. The plans generated using the Pop. Avg. weights result in 105 patients with a 95th percentile rectum dose error that is 4Gy larger than the LR model plans. Moreover, the Pop. Avg. plans result in 70 patients with a median rectum dose error that is 1 Gy larger than LR. Again, the model predicted distributions tend to be centred the bladder DVH curves are nearly identical for the Pop. Avg., LR, and IOM plans. This 305 weight difference allows the Pop. Avg. plan to achieve greater rectum sparing at almost no cost; entirely due to the more efficient utilization of the objective weight. 
IV. Discussion
Our models can predict new patient weight vectors that are comparable to the clinically 315 acceptable weight vectors determined by the IOM. Our aim was to replicate the IOM weights and thus the IOM treatment plans. The idea is to provide the planner with a "good" set of starting weights, from which only minor adjustment would be needed ideally. Interestingly, we observed that for 20% of our patients, the predicted weight vectors lead to treatment plans that are strictly better than the IOM treatment plans for all four bladder and rectum 320 clinical metrics. This implies that for 20% of patients no further personalization or work by the planner is needed to achieve clinically acceptable plans.
As more treatment plans are processed and used to train our models, there is potential for increased prediction accuracy. Since our models "learn" from historical plans, we can expect future plans to exhibit similar trade-offs, which may lead to a method of plan 325 standardization. Furthermore, because our models predict objective function weights, each planner will begin the treatment planning process at an informed position. This may cause a reduction in overall planning time and may potentially lead to improved clinical plans.
Weight prediction may also be used to strengthen existing automated treatment planning techniques by allowing them to consider and predict trade-offs between OARs.
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Although all three models (LR, KNN, MLR) generated treatments that were not statistically different in any clinical metrics, our results suggest that the LR model trended toward the most accurate for prostate cancer. We believe this result is likely due to low weight values for the femurs and PTV ring, which is a result of prostate treatment planning being predominately binomial in OAR trade-offs. However, a major limitation of the LR model 335 is that it is only applicable to tumor sites that have a bi-criteria trade-off. Fortunately, the MLR and KNN models, which can predict any number of objective weights, performed similarly. Thus, we believe that these advanced models have much broader applicability.
Application of the KNN and MLR methods to head-and-neck data, where many complex trade-offs are present, is the subject of future work. We acknowledge that there may exist other approaches for weight prediction and discuss one such method here. In this approach, we would use historical plans and patient features to train machine learning models that can predict achievable dose for multiple OARs. We would then use these dose metrics as input to an inverse optimization model to determine the DVH cloud area below the 10th percentile of all bladder (rectum) DVH cloud areas were classified as insensitive. For weight insensitive patients, personalized weight prediction is less valuable and it makes sense to employ a more streamlined prediction method such as KNN. Moreover, for highly insensitive patients, it may be possible to simply apply the Pop.
Determining a metric for classifying patient sensitivity is an important topic for further research. The ability to identify insensitive patients a priori will allow the treatment planner to manage their time and effort put into sparing an OAR that cannot be improved. In addition, if an OAR is insensitive the treatment planner may choose to give more weight 380 to another OAR where the marginal benefit in dose reduction will be much greater. In combination, the ability to predict patient sensitivity may significantly increase plan quality while simultaneously reducing planning time.
V. Conclusion
In this paper, we developed weight prediction methodologies that can simultaneously Lastly, this study introduces the idea of patient weight sensitivity, an important direction for future research, which may further reduce planning time while increasing plan quality through OAR sparing. Future work involves developing a methodology to determine patient sensitivity a priori and classify patients accordingly.
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